8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

January 16, 2007

(Date of the earliest event reported)

Simulations Plus, Inc.

(Exact name of registrant as specified in its charter)

California	000-32046	95-4595609
(State or other jurisdiction	(Commission	(I.R.S. Employer
of incorporation)	File Number)	Identification No.)

42505 10^th Street West, Lancaster, California 93534-7059

(Address of principal executive offices) (Zip Code)

661-723-7723

Registrant's telephone number, including area code

Item 2.01Results of Operations and Financial Condition

On January 16, 2007, Simulations Plus, Inc., a California corporation (the "Company"), issued a press release reporting financial results for the first fiscal quarter ending November 30, 2006. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

On the same date, the company’s CEO presented a conference call for investors to review the financial results for the first fiscal quarter ending November 30, 2006. A copy of the PowerPoint slides used as notes for this call is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

This report on Form 8-K (the "Report"), including the disclosures set forth herein, contains certain forward-looking statements that involve substantial risks and uncertainties. When used herein, the terms "anticipates," "expects," "estimates," "believes" and similar expressions, as they relate to us or our management, are intended to identify such forward-looking statements. Forward-looking statements in this Report or hereafter, including in other publicly available documents filed with the Securities and Exchange Commission (the "Commission"), reports to the stockholders of Simulations Plus, Inc., a California corporation (the "Company" or "us," "our" or "we") and other publicly available statements issued or released by us involve known and unknown risks, uncertainties and other factors which could cause our actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. Such future results are based upon management's best estimates based upon current conditions and the most recent results of operations. These risks include, but are not limited to, the risks set forth herein and in such other documents filed with the Commission, each of which could adversely affect our business and the accuracy of the forward-looking statements contained herein. Our actual results, performance or achievements may differ materially from those expressed or implied by such forward-looking statements.

Item 9.01Financial Statements and Exhibits

(c)Exhibits

99.1	Press release dated January 16, 2007.
99.2	PowerPoint presentation for the Investor Conference Call on January 16, 2007.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	SIMULATIONS PLUS, INC.
Dated: January 16, 2007	By: /s/ Momoko Beran
	Momoko Beran
	Chief Financial Officer

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press release dated January 16, 2007.
99.2	PowerPoint presentation for the Investor Conference Call on January 16, 2007.

EX-99.1

Exhibit 99.1

Simulations Plus Reports First Quarter FY2007 Financial Results

Record First Quarter Sees Pharmaceutical Revenues Jump 314%

LANCASTER, CA, November 9, 2006 - Simulations Plus, Inc. (AMEX: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today reported its preliminary financial results for the first quarter of its 2007 fiscal year (1Q07) ended November 30, 2006.

Ms. Momoko Beran, chief financial officer of Simulations Plus, stated: “Consolidated revenues for 1Q07 were $1,456,000, an increase of 78% from $819,000 in the first quarter of fiscal year 2006 (1Q06) and a new record for first quarters. Revenues from pharmaceutical software and services were up 314% to $824,000 from $199,000 in 1Q06. Revenues for our Words+ subsidiary for 1Q07 increased 2.0% to $632,000 from $620,000 in 1Q06. Gross profit increased 108% to $1,015,000 in 1Q07 from $629,000 in 1Q06. R&D expense increased 89% to $184,000 in 1Q07 from $97,000 in 1Q06, primarily due to expansion of our Life Sciences staff. Consolidated SG&A increased 20.4% to $757,000 in 1Q07, compared to $629,000 in 1Q06; however, as a percentage of sales, SG&A decreased from approximately 177% to approximately 53%. The major increases in expenses were selling expenses, such as commissions to dealers and trade shows, as well as printer rental, salaries, and payroll-related expenses such as health insurance and payroll taxes, which outweighed decreases in professional fees.

“Net income before taxes for 1Q07 increased $334,000 to $94,000 compared with a loss of $241,000 in 1Q06. First quarter earnings were impacted by a provision for income taxes of $21,000 that will not actually be paid, but rather will be a write-off from our deferred tax asset. Consolidated net earnings for the quarter increased to $73,000, or $0.01 per diluted share, as compared to a loss of $199,000, or $0.03 per diluted share for 1Q06, which means our trailing twelve months earnings increased from about $0.08 to about $0.12 per share. Cash at the end of 1Q07 was approximately $2,103,000, up from $932,000 at the end of 1Q06. With receivables due in the next few weeks, we expect cash to exceed $3 million in the very near future.”

Ms. Beran continued, “We’re now half way through our second fiscal second quarter, which will end on February 28. Pharmaceutical software and services revenues for the quarter are already ahead of last year’s second quarter. It appears at this time that our earlier guidance of an expected increase in total revenues of approximately a million dollars for FY07 over FY06 will be achieved in the first two quarters alone. We expect to provide updated guidance after the end of the second quarter.”

Ron Creeley, vice president of marketing and sales of Simulations Plus, noted, “A significant portion of 1Q07 pharmaceutical software and services revenues is due to new business, either as new companies or as new departments within existing large customers. We believe the adoption of simulation and modeling tools by medium and smaller companies is an indicator of the growing recognition by the thousands of such companies in the industry of the need for these tools in their research and development activities.”

Walt Woltosz, chairman and chief executive officer of Simulations Plus, said: “Fiscal year 2007 is off to the strongest start in our history, and it continues the trend of record-setting quarters from last year. The recent activity in the stock market indicates that we are finally being valued on our growth potential rather than on a trailing basis. We are focusing on growth, and that comes in one of two ways - selling more of what we have, and having more products and services to sell. Our more aggressive marketing and sales activities over the past 18 months are producing results, and we will continue to be aggressive in that area. We are on the lookout for additional accretive acquisition opportunities like the Bioreason and Sage Informatics deals we did last year, but recognizing that such deals don’t come along every day, we are also working on developing new products and product extensions internally. With our strong and continually improving cash position, we’ve made an investment in expanding our Life Sciences team to enable more rapid development of such new capabilities. This is partially reflected in the increase in R&D expense of almost $90,000 for the first quarter. We expect to add additional staff as we can identify and hire talented personnel who fit into the elite team we now have. I wish all of our shareholders could meet the employees of Simulations Plus and Words+ to see for themselves what a remarkably talented and dedicated group of people we have in every department.”

About Simulations Plus, Inc.

Simulations Plus, Inc. is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. We have two other businesses that are based on our proprietary technologies: a wholly owned subsidiary, Words+, Inc., which provides assistive technologies to persons with disabilities as well as a personal productivity tool for the mass market called Abbreviate!^™; and an educational software series for science students in middle and high schools known as FutureLab^™. For more information, visit our Web sites at www.simulations-plus.com and www.words-plus.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 - With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the Securities and Exchange Commission.

--Tables follow--

Simulations Plus, Inc. and Subsidiary

Consolidated Balance Sheet

(Unaudited)

November 30, 2006

ASSETS
Current assets
Cash and cash equivalents	$	2,102,782
Accounts receivable, net of allowance for doubtful accounts
and estimated contractual discounts of $32,711		1,214,114
Current portion of contracts receivable, net of discounts of $2,242		186,138
Inventory		233,906
Prepaid expenses and other current assets		56,897
Current portion of deferred tax		190,034
Total current assets		3,983,871
Capitalized computer software development costs,
net of accumulated amortization of $2,534,905		1,400,231
Property and equipment, net		102,278
Contracts receivable, net of discounts of $161		47,219
Customer relationships, net of accumulated amortization of $36,156		91,886
Deferred tax		889,816
Other assets		18,445
Total assets	$	6,533,746
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities
Accounts payable	$	140,548
Accrued payroll and other expenses		373,561
Accrued bonuses to officers		10,430
Accrued warranty and service costs		34,852
Deferred revenue		157,173
Total current liabilities		716,564
Long Term deferred revenue		62,501
Total liabilities		779,065
Commitments and contingencies
Shareholders' equity
Preferred stock, $0.001 par value
10,000,000 shares authorized
no shares issued and outstanding		-
Common stock, $0.001 par value
20,000,000 shares authorized
7,449,496 shares issued and outstanding		3,802
Additional paid-in capital		5,287,207
Retained Earnings		463,672
Total shareholders' equity		5,754,681
Total liabilities and shareholders' equity	$	6,533,746

Simulations Plus, Inc. and Subsidiary

Consolidated Statements of Operations

For the Three Months Ended November 30, 2006 and 2005

(Unaudited) 

	2006			2005
Net sales	$	1,456,451		$	818,815
Cost of sales		441,440			331,597
Gross profit		1,015,011			487,218
Operating expenses
Selling, general, and administrative		756,777			628,756
Research and development		183,627			97,222
Total operating expenses		940,404			725,978
Income (Loss) from operations		74,607			(238,760	)
Other income (expense)
Interest income		15,928			3,481
Miscellaneous income		358			50
Gain (Loss) on currency exchange		2,972			(5,302	)
Total other income (expense)		19,258			(1,771	)
Income (Loss) before income taxes		93,865			(240,531	)
Benefit from (provision for) income taxes
Benefit from (provision for) income tax		(20,650	)		42,000
Total benefit from (provision for) income taxes		(20,650	)		42,000
Net income (loss)	$	73,215		$	(198,531	)
Basic earnings (loss) per share	$	0.01		$	(0.03	)
Diluted earnings (loss) per share	$	0.01		$	(0.03	)
Weighted-average common shares outstanding*
Basic		7,444,551			7,298,668
Diluted		8,548,560			7,298,668
* The number of shares at November 30, 2005 have been retroactively restated
to reflect a 2-for-1 stock split that occurred on August 14, 2006.

EX-99.2

Exhibit 99.1

Investor Relations Conference Call January 16, 2007

1

Introduction and Welcome•Introduction and welcome •Why conference call now? -High interest and activity -November volume 432,000 shares -December volume 1.6 MM shares, most after December 14 -January volume to date ~1.8 MM shares (9 trading days) -Record close at $7.05 on Friday •Agenda -1Q 2007 summary (September 1 -November 30, 2006) -Strategy going forward -Questions and Answers

2

1Q 2007 Summary•Gross revenues = $1.456 MM (up 77.8%) -Pharmaceutical revenues up 314% •SG&A = $757,000 (up 20.4%) -As a percent of sales, down from 177% to 53% •R&D = $317,000 ($133,000 capitalized, $184,000 expensed) -1Q FY06 $460,000, with $363,000 capitalized and $246,000 expensed) •Gross profit = $1,015,000 (up 108%) -Revenues increase of $637,000 resulted in gross profit increase of $528,000 (83%) •Income Before Income Taxes = $94,000 -1Q FY06 loss of $240,000 -Revenues increase of $637,000 resulted in IBIT increase of $334,000 (52%) •Net Earnings = $73,000 ($0.01/share) -1Q FY06 loss of $198,000 ($0.03/share) -Revenues increase of $637,000 resulted in net earnings increase of $271,000 (43%) -Trailing twelve months earnings increased 50% from $0.08 to $0.12/share •Cash flow = $418,000 -1Q FY06 ($822,000) -acquisition of Bioreason assets used $826,000 cash -Cash is now >$2 million, expect >$3 million within the next few weeks •Staffing: Life Sciences team increased with addition of 4 Ph.D. scientists, another one accepted offer today to start in March

3

Progress•ADMET Predictor/ADMET Modeler -Combined into one program and released as ADMET Predictor 2.0 in September -Combined capability expected to increase appeal in a very competitive market -Continues to enjoy reputation as most accurate structure-property prediction program currently available

4

Progress -2•ClassPharmer -Japan NIHS (equivalent of FDA) signed 5-year license -Version 4.2 released in November •Pipeline Pilot integration •Improvements in classification algorithms, speed, and number of molecules that can be handled in a single run •DDDPlus -Version 2.0 released in November -Sales beginning to pick up

5

Progress -3•GastroPlus -Version 5.2 released in November -Continues to be the “Gold Standard” in the industry for its market niche -FDA license announced during the 2ndquarter -Ongoing contract effort at one FTE with large pharmacontinuing to improve PBPK

6

Progress -4•Contract studies -Increasing demand for consulting services -2 studies in FY05, 3 in FY06, 5 already this year -Industry appears to have a shortage of expertise in simulation and modeling personnel as evidenced by employment ads we see almost daily

7

Progress -5•Words+ subsidiary -Consulting marketing and sales manager very active -New California sales rep added as employee -Preparations for release of Windows Vista underway with Microsoft assistance

8

Strategy Going Forward•Expand product line and services -Pharmaceutical software •Respond to customer requests for enhancements to existing products •New product development -Completion of MembranePlus™ -Others not yet public •Continue seeking opportunities to partner or acquire new products -Pharmaceutical consulting services •Expanding Simulation Technologies team to handle rapidly growingdemand for consulting services -Words+ subsidiary •Expanded platforms for SAM™ software •Internationalize software (French, German) to expand markets •Seek acquisition opportunities •SBIR grant proposal submitted in December •Continue aggressive marketing and sales activities begun last year in both companies •Focus on growth -seek accretive acquisitions, develop in-house

9

Guidance•Guidance provided in November conference call was to expect increase in total revenues of at least $1 million •As of today, pharmaceutical revenues are already up over $980,000, after only 1 ½ quarters •We expectto issue revised guidance after the end of the second quarter

10

Summary•Company is strong and growing -focus is on further growth •No debt, strong cash position •Strong cash flow and consistent growth in shareholders’ equity are the indicators of demonstrated growth •Dedicated and extremely talented workforce working to grow the product lines in both businesses •Expanding marketing and sales efforts in both businesses •Slides available by e-mail on request through info@simulations-plus.com

11

Questions?

12